Omeprazole
NDC Package 80175-0715-3

11-digit billing NDC: 80175071503

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Omeprazole is 1.1 Treatment of Active Duodenal UlcerOmeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Marketed by Central Packaging, this product is identified by NDC 80175-0715 and is authorized under FDA application ANDA075576.

Identification & Billing

NDC Package Code
80175-0715-3
Package Description
30 CAPSULE, DELAYED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
80175071503
RxNorm Crosswalk
  • RxCUI: 198051 - omeprazole 20 MG Delayed Release Oral Capsule
  • RxCUI: 198051 - omeprazole 20 MG (as omeprazole magnesium 20.6 MG) Delayed Release Oral Capsule

Clinical Specifications

Proprietary Name
Omeprazole
Dosage Form
-
Usage Information
1.1 Treatment of Active Duodenal UlcerOmeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer RecurrenceEradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple TherapyOmeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual TherapyOmeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section].1.3 Treatment of Active Benign Gastric UlcerOmeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults.1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD)Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older.1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERDPediatric Patients 2 Years of Age to AdultsOmeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERDOmeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months.1.7 Pathological Hypersecretory ConditionsOmeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.

Regulatory & Marketing

Labeler Name
Central Packaging
FDA Application #
ANDA075576
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-25-2019
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 80175-0715-3 identifies a specific commercial package of 30 capsule, delayed release in 1 bottle of Omeprazole, labeled by Central Packaging. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Central Packaging on October 25, 2019. The current certification is valid through December 31, 2022.

How is this Central Packaging product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 80175071503. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
80175-0715-3
11-Digit CMS (5-4-2)
80175-0715-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.